论文部分内容阅读
目的 :观察莫沙必利治疗功能性消化不良的有效性及安全性。方法 :采用双盲随机对照研究 ,2 55名功能性消化不良病人。随机分为 2组 :莫沙必利组 12 7例 (男性 58例 ,女性 6 9例 ,年龄 4 0a±s 12a)用莫沙必利 5mg ,po ,tid ;多潘立酮组 12 8例(男性 6 1例 ,女性 6 7例 ;年龄 39a± 12a)用多潘立酮 10mg ,po ,tid。疗程均为 4wk。结果 :莫沙必利治疗 4wk ,上腹疼痛、上腹饱胀、嗳气、进食减少及早饱等症状的总有效率分别为 77.8% ,86 .6 % ,82 .5% ,87.3% ,87.2 %。明显高于多潘立酮的6 3.5% ,75.0 % ,6 9.6 % ,74 .1% ,74 .5%。莫沙必利组治疗后胃半排空时间缩短 15min± 13min ,明显高于多潘立酮组 5min± 16min。结论 :莫沙必利是一种新型安全有效的治疗功能性消化不良的药物。
Objective: To observe the efficacy and safety of mosapride in treating functional dyspepsia. Methods: A double-blind, randomized, controlled trial of 2 55 functional dyspepsia patients. Randomly divided into two groups: Mosapride group 12 7 cases (58 males and 69 females, age 40a ± s 12a) with mosapride 5mg, po, tid; domperidone group of 128 patients (male 6 1 case, 67 females; age 39a ± 12a) with domperidone 10mg, po, tid. Treatment are 4wk. RESULTS: The total effective rates of mosapride treatment for 4 weeks, upper abdominal pain, upper abdominal fullness, belching, premature ejaculation and food intake were 77.8%, 86.6%, 82.5%, 87.3%, 87.2% . Significantly higher than domperidone 6 3.5%, 75.0%, 6 9.6%, 74.1%, 74.5%. Mosapride group after treatment gastric emptying time shortened 15min ± 13min, significantly higher than domperidone group 5min ± 16min. Conclusion: Mosapride is a new and safe drug for the treatment of functional dyspepsia.